Trends in Hyperpolypharmacy Before and After Nursing Home Admission Among Older Adults in Ontario, Canada.

Community Hyperpolypharmacy Nursing home Older adults Psychotropics

Journal

The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry
ISSN: 1545-7214
Titre abrégé: Am J Geriatr Psychiatry
Pays: England
ID NLM: 9309609

Informations de publication

Date de publication:
14 Sep 2024
Historique:
received: 18 07 2024
revised: 06 09 2024
accepted: 10 09 2024
medline: 5 10 2024
pubmed: 5 10 2024
entrez: 4 10 2024
Statut: aheadofprint

Résumé

To examine trends in the prevalence of hyperpolypharmacy prior to and following nursing home admission in Ontario, Canada. We conducted a cohort study of adults aged 75+ years admitted to nursing homes between 2017 and 2020 using health administrative data (n = 61,470). The prevalence of hyperpolypharmacy (≥10 dispensed drugs) was assessed quarterly from ten years prior to 1.5 years following admission. Over ten years, the prevalence of hyperpolypharmacy increased from 4.4% to 12.0% (+0.2% per quarter, [p <0.001]) and further increased after admission (13.8%). Antidepressants (three-fold), antipsychotics (seven-fold) and cholinesterase inhibitors (14-fold) increased significantly over ten years prior to admission, while cardiovascular medications peaked 4 to 5 years prior to admission. While hyperpolypharmacy increased nearly three-fold in the ten years prior to nursing home admission, patterns varied by drug class. Increasing hyperpolypharmacy throughout the life course suggests opportunities exist for medication reconciliation in community and nursing home settings.

Identifiants

pubmed: 39366872
pii: S1064-7481(24)00454-8
doi: 10.1016/j.jagp.2024.09.005
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

Copyright © 2024 American Association for Geriatric Psychiatry. Published by Elsevier Inc. All rights reserved.

Auteurs

Laura C Maclagan (LC)

ICES (LCM, AE, AH, MAC, MT, CJM, SEB), Toronto, Ontario, Canada.

Abby Emdin (A)

ICES (LCM, AE, AH, MAC, MT, CJM, SEB), Toronto, Ontario, Canada; Dalla Lana School of Public Health (AM, SEB), University of Toronto, Ontario, Canada.

Anjie Huang (A)

ICES (LCM, AE, AH, MAC, MT, CJM, SEB), Toronto, Ontario, Canada.

Michael A Campitelli (MA)

ICES (LCM, AE, AH, MAC, MT, CJM, SEB), Toronto, Ontario, Canada.

Mina Tadrous (M)

ICES (LCM, AE, AH, MAC, MT, CJM, SEB), Toronto, Ontario, Canada; Leslie Dan Faculty of Pharmacy (MT), University of Toronto, Ontario, Canada; Women's College Research Institute (MT, SEB), Toronto, Ontario, Canada.

Andrea Iaboni (A)

Department of Psychiatry, Faculty of Medicine (AI), University of Toronto, Ontario, Canada; KITE-Toronto Rehabilitation Institute (AI), University Health Network, Toronto, Ontario, Canada.

Luis Viana (L)

North West Telepharmacy Solutions (LV), Ontario, Canada.

Colleen J Maxwell (CJ)

ICES (LCM, AE, AH, MAC, MT, CJM, SEB), Toronto, Ontario, Canada; School of Pharmacy (CJM), University of Waterloo, Kitchener, Ontario, Canada.

Susan E Bronskill (SE)

ICES (LCM, AE, AH, MAC, MT, CJM, SEB), Toronto, Ontario, Canada; Dalla Lana School of Public Health (AM, SEB), University of Toronto, Ontario, Canada; Women's College Research Institute (MT, SEB), Toronto, Ontario, Canada; Sunnybrook Research Institute (SEB), Toronto, Ontario, Canada. Electronic address: susan.bronskill@ices.on.ca.

Classifications MeSH